title: Clinical trial of indomethacin in Alzheimer's disease.
abstract: In a 6-month, double-blind, placebo-controlled study, 100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (+/- 1.8%), whereas placebo patients declined 8.4% (+/- 2.3%)--a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.
authors.affiliation: L.J. Roberts Center for Alzheimer's Research, Sun Health Research Institute, AZ 85372.
authors.forename: J
authors.initials: J
authors.lastname: Rogers
authors.forename: L C
authors.initials: LC
authors.lastname: Kirby
authors.forename: S R
authors.initials: SR
authors.lastname: Hempelman
authors.forename: D L
authors.initials: DL
authors.lastname: Berry
authors.forename: P L
authors.initials: PL
authors.lastname: McGeer
authors.forename: A W
authors.initials: AW
authors.lastname: Kaszniak
authors.forename: J
authors.initials: J
authors.lastname: Zalinski
authors.forename: M
authors.initials: M
authors.lastname: Cofield
authors.forename: L
authors.initials: L
authors.lastname: Mansukhani
authors.forename: P
authors.initials: P
authors.lastname: Willson
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D008297:Male; D009483:Neuropsychological Tests; D010919:Placebos
chemical_list: D010919:Placebos; D007213:Indomethacin